Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Telethon seeks a visionary Head of Lipid Nanoparticle Core to design, implement and manage a cross‑institute Core at SR‑TIGET (Milan) with regular travel to TIGEM. You will shape a strategic platform supporting internal research and translational programs.
The role requires a PhD in chemistry or related field, 5+ years post‑doc experience in LNPs, leadership skills, and proven ability to manage cross‑functional teams and external collaborations.
FT is seeking an experienced and forward-thinking scientist to serve as Head of Lipid Nanoparticle Core, leading an integrated initiative across TIGEM and SR-TIGET. The position offers a unique opportunity to shape a strategic technology platform within the globally recognized Fondazione Telethon R&D ecosystem. The successful candidate will design, implement, and manage the Core, supporting internal research groups and translational programs.
The position is based at SR-TIGET (Milan) and requires regular travel between the two sites.
Key Responsibilities
WHAT WE OFFER
Fondazione Telethon is an Equal Opportunity Employer committed to increasing the diversity of its staff and provides employment opportunities regardless of individual’s age, color, disability, gender, national origin, religion, or sexual orientation.
Fondazione Telethon (FT) is a leading biomedical charity committed to advancing research into tangible therapeutic options for people living with rare genetic diseases. Through its affiliated research institutes – TIGEM (Naples) and SR‑TIGET (Milan) – FT has established an internationally recognized track record in the development of novel gene therapy approaches, including AAV- and Lentiviral Vector-mediated gene transfer, and their clinical application, with more than 170 patients successfully treated to date. Furthermore, FT has pioneered the development and application of genome and epigenome editing approaches for precise gene correction and gene silencing, and it remains at the forefront of these technologies.
To support the preclinical advancement of these cutting‑edge approaches, FT is now expanding its capabilities in the non‑viral gene delivery space , aiming at establishing a cross‑institute Core facility dedicated to the production and characterization of Lipid Nanoparticles (LNPs).